Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) FCF Margin (2020 - 2025)

Historic FCF Margin for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q1 2025 value amounting to 4767.44%.

  • Rani Therapeutics Holdings' FCF Margin changed N/A to 4767.44% in Q1 2025 from the same period last year, while for Sep 2025 it was 2315.5%, marking a year-over-year decrease of 53805500.0%. This contributed to the annual value of 3479.38% for FY2024, which is N/A changed from last year.
  • Per Rani Therapeutics Holdings' latest filing, its FCF Margin stood at 4767.44% for Q1 2025.
  • In the past 5 years, Rani Therapeutics Holdings' FCF Margin registered a high of 1123.25% during Q3 2023, and its lowest value of 4767.44% during Q1 2025.
  • Moreover, its 4-year median value for FCF Margin was 340.88% (2021), whereas its average is 291.34%.
  • Over the last 5 years, Rani Therapeutics Holdings' FCF Margin had its largest YoY gain of -18210300bps in 2024, and its largest YoY loss of -18210300bps in 2024.
  • Over the past 4 years, Rani Therapeutics Holdings' FCF Margin (Quarter) stood at 293.93% in 2021, then skyrocketed by 432bps to 975.69% in 2023, then crashed by -187bps to 845.33% in 2024, then tumbled by -464bps to 4767.44% in 2025.
  • Its FCF Margin was 4767.44% in Q1 2025, compared to 845.33% in Q4 2024 and 975.69% in Q4 2023.